Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually.
Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily.
Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Because changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under careful monitoring.
Special populations
Patients with renal impairment
The efficacy and safety of this medicine vary according to renal function, and dose adjustment according to renal function is required. Therefore, assessment of renal function is recommended before treatment and periodically thereafter.
No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.
Improvement of glycemic control in adults with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to improve blood sugar control in adult patients with type 2 diabetes in conjunction with dietary and exercise therapy. The combination of Empagliflozin, Sitagliptin, and Metformin helps effectively lower blood sugar levels. This contributes to improving the condition of patients who have difficulty managing blood sugar.
How to take
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually.
Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily.
Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Because changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under careful monitoring.
Special populations
Patients with renal impairment
The efficacy and safety of this medicine vary according to renal function, and dose adjustment according to renal function is required. Therefore, assessment of renal function is recommended before treatment and periodically thereafter.
No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.
Precautions
This medication is used for diabetes treatment and contains three ingredients. There are several precautions to be aware of when taking this medication.
First, the Sitagliptin component may rarely cause severe allergic reactions. If symptoms like skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult a doctor.
Second, Sitagliptin may cause acute pancreatitis, an inflammation of the pancreas, so if abdominal pain, vomiting, or loss of appetite occur while taking it, promptly inform a healthcare provider.
Third, the Metformin component may rarely lead to a serious condition called lactic acidosis. This condition can be accompanied by symptoms such as vomiting, abdominal pain, muscle pain, difficulty breathing, and fatigue. Patients with impaired kidney function, severe infections, dehydration, or heart failure should be particularly cautious.
Fourth, this medication is not recommended for patients with type 1 diabetes, acute metabolic acidosis, severe renal impairment, or acute heart failure.
Fifth, the use of this medication should be temporarily interrupted before and after surgery or during conditions of severe infection or dehydration, and should be restarted after recovery.
Sixth, dosage adjustments may be necessary based on kidney function, and regular kidney function tests are recommended. Particularly elderly patients or those with reduced kidney function should undergo more frequent testing.
Seventh, this medication may cause hypoglycemia, so blood sugar levels should be closely monitored, especially when taken with insulin or sulfonylurea medications.
Eighth, during the use of this medication, genital infections or urinary tract infections may occur, so immediate treatment should be sought if symptoms appear.
Ninth, symptoms of low blood pressure or dehydration may occur due to reduced fluid volume, so elderly patients or those with low blood pressure should exercise caution and discontinue use during dehydration.
Tenth, this medication is not recommended for patients with liver dysfunction, and healthcare providers should be informed immediately if symptoms of liver dysfunction arise.
Finally, this medication should be swallowed whole and not chewed or crushed. The tablet shell may be excreted in the stool, but this is a normal occurrence.
Regular blood tests and health assessments should be conducted to ensure safe treatment while taking this medication.
Side effects
Severe hypersensitivity reactions
anaphylaxis
angioedema
Stevens-Johnson syndrome
exfoliative skin diseases
acute pancreatitis
lactic acidosis
hypoglycemia
dyspepsia
abdominal pain
Show 146 moreCollapse
hyperglycemia
inadequately controlled diabetes
genital pruritus
vulvar pruritus
vaginal infections
weight loss
thirst
rash
urticaria
angioedema
hypovolemia
increased urination
urinary retention
interstitial nephritis
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
increased hematocrit
vulvovaginal candidiasis
balanitis
urinary tract infections
perineal necrosis
ketoacidosis
urosepticemia
pyelonephritis
headache
cerebral infarction
intracranial aneurysm
fever
vascular stent stenosis
vascular stent thrombosis
increased alanine aminotransferase
increased aspartate aminotransferase
urolithiasis
acute kidney injury
cervicitis
hyponatremia
diabetic foot
lumbosacral pain
glaucoma
pathological myopia
retinal detachment
retinal vein occlusion
macular retinal detachment
limb injuries
road traffic accidents
splenic injury
sternal fractures
angina
Prinzmetal angina
coronary artery disease
deep vein thrombosis
benign neoplasm of the ampulla of Vater
benign ovarian tumors
bladder cancer
gastric cancer
pancreatic adenocarcinoma
colorectal cancer
thyroid cancer
uterine leiomyoma
acute cholecystitis
autoimmune hepatitis
cholelithiasis
anxiety
depression
sleep disorders
otalgia
orthostatic dizziness
dizziness
anemia
lymphadenopathy
hypothyroidism
thyroid nodules
constipation
diarrhea
dyspepsia
gastritis
upper respiratory tract infections
herpes zoster
vertigo
chest discomfort
chest pain
asthenia
weight loss
vulvar pruritus
genital pruritus
dyslipidemia
hyperglycemia
lumbar spinal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
musculoskeletal pain
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
macular fibrosis
ocular discomfort
conjunctival congestion
eyelid edema
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
exertional dyspnea
wet cough
allergic rhinitis
residual phlegm
cough
skin lacerations
bruising
rib fractures
concussion
corneal abrasion
falls
hand fractures
iliolumbar ligament syndrome
open eye injuries
pelvic fractures
unstable angina
arteriosclerosis
diabetic vascular complications
peripheral artery occlusive disease
erectile dysfunction
acute renal failure
severe and disabling arthralgia
blistering-like pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius to safely preserve the medication's efficacy.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.